T-DM1 Confers Lower Cardiotoxicity Risk in HER2+ Advanced Breast Cancer

The use of ado-trastuzumab emtansine (T-DM1; Kadcyla) was associated with the lowest incidence of left ventricular ejection fraction (LVEF) decrease compared with 3 other trastuzumab-based regimens in the treatment of patients with HER2-positive…